Back to Results

A Multicenter, Open-Label, Non-Randomised First in Human Study of NG-350A in Patients with Metastatic or Advanced Epithelial Tumours (FORTITUDE)

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

Disease must be epithelial ( carcinoma or adenocarcinoma )

Phase

I - Research Studies that focus on the safety of a drug. The goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These studies usually involve a small number of participants.

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Ross Camidge,  MD, PhD

Ross Camidge, MD, PhD

Study ID

Protocol Number: 19-1147

ClinicalTrials.gov: NCT03852511

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers